ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCCN Updates Breast Cancer Guidelines for Patients

October 31, 2003

In Brief: Esparza, Young, Busch, Rush Head Oncology Societies; Hipple Centers Honors Harry Eagle

June 2, 1989

Breast Cancer Incidence Goes Up, Most of it in Early, Local Stages

July 11, 1988

Heart Institute Withdraws Sponsorship Of Breast Cancer Prevention Trial

October 27, 1995

“Imaginary Treatments,” “Wonderful Cures”

June 6, 1997

RFPS, RFAs Available

September 23, 1994